Italia markets closed

VERA Jul 2024 40.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,25000,0000 (0,00%)
In data: 01:02PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,2500
Aperto0,2500
Denaro0,0000
Domanda3,3000
Prezzo d'esercizio40,00
Scadenza2024-07-19
Min-Max giorno0,2500 - 0,2500
Contratto - Min-MaxN/D
Volume4
Open Interest18
  • GlobeNewswire

    Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

    Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN therapy Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA),

  • GlobeNewswire

    Vera Therapeutics Scheduled to Present at September Investor Conferences

    BRISBANE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at four investor conferences being held next month. Investor Conference Details: Citi 18th Annual BioPharma ConferenceFormat: Management hostin

  • GlobeNewswire

    Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

    Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA CongressInitiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgANStrong balance sheet expected to fund operations to early 2026 BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative tr